Reviewed listing: NASDAQ:VRTX · Analysis dated Oct 21, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
Vertex develops and sells medicines for serious diseases. Most of its revenue still comes from treating cystic fibrosis.
What supports the business?
The established business is profitable. In the first half, operating cash flow increased from around 1.89 to 2.55 billion USD.
What could improve?
New medicines and the acquired offerings could broaden the business. For that to work, approvals, sales, and earnings must justify the high investments.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
At 514.65 USD, an attractive entry price is not sufficiently supported. The price is roughly 30 times the most recently reported annual earnings; the full financial effects of the acquisition remain unclear.
What is the main risk?
Vertex is highly dependent on one disease group. New treatments may fail or grow more slowly, while research, sales, and the large acquisition continue to consume cash.
What is the overall assessment?
Vertex generates substantial cash from cystic fibrosis drugs and is building additional business areas. At the reference price of 514.65 USD, however, I do not consider the stock a substantiated opportunity: following the major Crinetics acquisition, key details on the capital base and ongoing earnings power are still missing. The price assessment remains open; the company remains worth watching.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign inSources used in the analysis
- Original source 1 · investors.vrtx.com · Aug 03, 2026
- Original source 2 · www.sec.gov · Aug 04, 2026
- Original source 3 · investors.vrtx.com · Feb 13, 2026
- Original source 4 · investors.vrtx.com · Jul 06, 2026
- Original source 5 · investors.vrtx.com · Sep 01, 2026
- Original source 6 · investors.vrtx.com · Sep 22, 2026
- Original source 7 · investors.vrtx.com · Oct 09, 2026
- Original source 8 · investors.vrtx.com · Oct 07, 2026
- Original source 9 · investors.vrtx.com · Oct 20, 2026
- Original source 10 · api-v4.fcsapi.com